All In Biotech

Drug Trial Radar · NCT03811912

Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata

A Randomized Parallel-Group Study to Evaluate the Efficacy and Tolerability of Two Dosing Regimens of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

Last checked: Nov 19, 2026Latest source record: Dec 9, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

57

Actual

Start

Mar 21, 2019

Primary completion

Nov 21, 2019

Study completion Nov 21, 2019

Sponsor

Lead sponsor
Concert PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jan 22, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy and tolerability of once-daily versus twice-daily dosing of CTP-543, in adult patients with chronic, moderate to severe alopecia areata.

Conditions

  • Alopecia Areata

Interventions

  • CTP-543Drug

    CTP-543 administered as 8 mg tablet.

  • CTP-543 Matching PlaceboDrug

    Administered as tablets to aid treatment masking.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relative Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24Time frame: Baseline, Week 24

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Investigative Site

    Irvine, California

  • Investigative Site

    San Francisco, California

  • Investigative Site

    New Haven, Connecticut

  • Investigative Site

    Boynton Beach, Florida

  • Investigative Site

    Boston, Massachusetts

  • Investigative Site

    Boston, Massachusetts

  • Investigative Site

    Fridley, Minnesota

  • Investigative Site

    Portsmouth, New Hampshire

  • Investigative Site

    Winston-Salem, North Carolina

  • Investigative Site

    Portland, Oregon

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.